518. Model-informed Dose Selection of Dual Toll-like Receptor 7/8 Inhibitor Enpatoran (M5049) for the Treatment of COVID-19 Pneumonia

por Klopp-Schulze, Lena, Shaw, Jamie, Dong, Jennifer, Khandelwal, Akash, Adams, Elizabeth, Yu, Dongzi, Goteti, Kosalaram
Publicado 2021

Applying Modeling and Simulations for Rational Dose Selection of Novel Toll‐Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need

por Klopp‐Schulze, Lena, Shaw, Jamie V., Dong, Jennifer Q., Khandelwal, Akash, Vazquez‐Mateo, Cristina, Goteti, Kosalaram
Publicado 2022

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen

por Klopp-Schulze, Lena, Mueller-Schoell, Anna, Neven, Patrick, Koolen, Stijn L. W., Mathijssen, Ron H. J., Joerger, Markus, Kloft, Charlotte
Publicado 2020

DNA residence time is a regulatory factor of transcription repression

por Clauß, Karen, Popp, Achim P., Schulze, Lena, Hettich, Johannes, Reisser, Matthias, Escoter Torres, Laura, Uhlenhaut, N. Henriette, Gebhardt, J. Christof M.
Publicado 2017

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

por Vugmeyster, Yulia, Wilkins, Justin, Koenig, Andre, El Bawab, Samer, Dussault, Isabelle, Ojalvo, Laureen S., De Banerjee, Samrita, Klopp‐Schulze, Lena, Khandelwal, Akash
Publicado 2020

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies

por Mueller-Schoell, Anna, Klopp-Schulze, Lena, Michelet, Robin, van Dyk, Madelé, Mürdter, Thomas E., Schwab, Matthias, Joerger, Markus, Huisinga, Wilhelm, Mikus, Gerd, Kloft, Charlotte
Publicado 2021

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups

por Mueller-Schoell, Anna, Michelet, Robin, Klopp-Schulze, Lena, van Dyk, Madelé, Mürdter, Thomas E., Schwab, Matthias, Joerger, Markus, Huisinga, Wilhelm, Mikus, Gerd, Kloft, Charlotte
Publicado 2021

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

por Port, Andreas, Shaw, Jamie V., Klopp‐Schulze, Lena, Bytyqi, Afrim, Vetter, Claudia, Hussey, Elizabeth, Mammasse, Nadra, Ona, Victor, Bachmann, Angelika, Strugala, Denis, Reh, Christian, Goteti, Kosalaram
Publicado 2021